Glucose fluctuation and its influence on flow mediate dilation after different interventions in the patients with impaired glucose regulation: A Prospective, Randomized, Controlled Trial

Glucose fluctuation on flow mediate dilation and the related interventional trails

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003820

Enrollment

Unknown

Registered

2013-11-10

Start date

2013-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Lifestyle intervention group:Diet and exercise interventions

Acarbose intervention group:Diet, exercise and acarbose interventions

Probucol intervention group:Diet, exercise and Probucol interventions

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years; 2. BMI >18.5 kg/m2; 3. No severe heart, lung, liver or renal dysfunctions; 4. Patients with IGR (Standards of WHO1999): 6mmol/L =< Fasting blood glucose =< 7mmol/L 2h Postprandial blood glucose (75 grams OGGT) =< 7.8mmol/L; Fasting blood glucose =< 6.1mmol/L, 7.8mmol/L =< 2h Postprandial blood glucose =< 11.1mmol/L; 6mmol/L =< Fasting blood glucose =< 7mmol/L, 7.8mmol/L =< 2h Postprandial blood glucose =< 11.1mmol/L; 5. Any drug might influence the metabolism of blood glucose was not used within 1 month before and during the trail; 6. The patients sign the information consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with the history or symptoms of glaucoma or increased intraocular pressure; 2. Patients with the history of gastric ulcer; 3. Patients with interstitial pneumonia; 4. Patients with unstable angina pectoris or severe angina pectoris, and patients with myocardial infarction or the history of myocardial infarction; 5. Patients with congestive heart failure or the history of congestive heart failure; 6. Patients with takayasu arteritis, raynaud's disease, cold injury of vascular disease or other ischemic diseases; 7. Patients prescribed with vasodilators on chronic artery obliterans within 1 week before screening; 8. Patients with history of acute respiratory infection within 4 weeks before screening; 9. Patients with obvious hepatic or renal disease (AST and ALT > 2 folds of the upper limits of normal range respectively, Creatinine > 1.2 folds of the upper limit of normal range; 10. PT and APPT over the upper limits of normal range respectively or Fbg 160 mmHg or diastolic pressure >100 mmHg during antihypertensive treatment; 12. Patients with autoimmune disorders or any fatal diseases; 13. Pregnant and lactation women; 14. Patients with psychological disease or poor self-cognition; 15. Patients with allergic history to similar drugs or recent allergy; 16. Necessary for the prohibited drugs in the trail; 17. Patients took part in other new drug clinical trials in recent 3 months; 18. Other conditions the investigators think not permitted in the trail.

Design outcomes

Primary

Measure	Time frame
Flow mediate dilation: Vascular diameter; Basic of blood flow (ml/min); Reactive hyperemia blood flow(ml/min); Nitroglycerin blood flow(ml/min).;Glucose fluctuation related biomarkers;	—

Secondary

Measure	Time frame
Intima-media thickness;Vascular stiffness: C1; C2; AI; PWVß; ß; Ep; AC.;Lower extremity arterial occlusive disease related biomarkers: ICAM-1; VCAM-1; McP-1; sP-selectin; sCD40L; TM; hs-CRP; Ox-LDL; 8-OHdGPGF2a; TC; LDL-C; HDL-C; TG; apoB;	—

Countries

China

Contacts

Public ContactXingwu Ran

West China Hospital, Sichuan University

ranxingwu@163.com+86 028 81812305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026